3,024
Participants
Start Date
May 31, 2012
Primary Completion Date
December 31, 2015
Study Completion Date
January 31, 2016
amiodarone
300 mg will be given IV/IO push for reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 150 mg will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 150 mg, followed by a second dose of 150 mg if the VF/pulseless VT persists.
Lidocaine
120 mg will be given IV/IO push with reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 60 mg will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 60 mg, followed by a second dose of 60 mg if the VF/pulseless VT persists.
Normal saline
6 cc of normal saline (NS) will be given IV/IO push for reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 3 cc will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 3 cc, followed by a second dose of 3 cc if the VF/pulseless VT persists.
The Pittsburgh Resuscitation Network, University of Pittsburgh, Pittsburgh
Alabama Resuscitation Center, Birmingham
Milwaukee Resuscitation Network, Medical College of Wisconsin, Milwaukee
Dallas Center for Resuscitation Research, University of Texas Southwestern Medical Center, Dallas
UCSD-San Diego Resuscitation Center, San Diego
Portland Resuscitation Outcomes Consortium, Oregon Health & Sciences University, Portland
Seattle-King County Center for Resuscitation Research, University of Washington, Seattle
University of Ottawa/University of British Columbia Collaborative RCC, Ottawa Health Research, Ottawa
Toronto Regional Resuscitation Research Out-of-Hospital Network, University of Toronto, Toronto
Collaborators (1)
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Heart and Stroke Foundation of Canada
OTHER
American Heart Association
OTHER
Defence Research and Development Canada
INDUSTRY
U.S. Army Medical Research and Development Command
FED
University of Washington
OTHER